AlloDx Presents Research Advances at Major Scientific Meetings

In the golden autumn of October, the harvest season, two authoritative academic events in the field of nephrology and organ transplantation in China - the 28th Academic Annual Meeting of the Chinese Society of Nephrology (CCSN 2025) and the 30th Academic Annual Meeting of the Chinese Society of Organ Transplantation (CSOT 2025) were held in Zhengzhou and Changchun. Experts and scholars from all over the country gathered together to share fruitful scientific research results, exchange cutting-edge advances in the discipline, and explore clinical diagnosis and treatment experiences.

Relying on its years of dedicated accumulation and continuous innovative R&D capabilities in the field of kidney disease, AlloDx presented a number of research results at the two major events, and won the honor of oral report and poster communication respectively.

In the field of organ transplantation, AlloDx is based on its deep accumulation in the direction of donor-derived cell-free DNA (dd-cfDNA). It has not only achieved a breakthrough in domestic detection technology from 0 to 1, but also led it to achieve a leap from "quantification" to "positioning". The company's independently developed second-generation liquid biopsy technology, cPRISM-seq (Cis-Parallel Read Integrated SNP and Methylation Sequencing), can simultaneously capture SNP and methylation dual markers in the same read length, improving the accuracy of traditional traceability analysis by an order of magnitude.

In kidney disease research, AlloDx also has two notable achievements. One is the antigen-antibody dual-targeted proximity extension analysis technology for the complement system (AADT-PEA), which simultaneously detects 11 complement factors and their autoantibodies, outperforming traditional ELISA in linear correlation (R² > 0.996) and detection sensitivity (data from the study), providing an efficient, high-throughput new tool for precise diagnosis of complement-abnormality-related kidney disease. The other is a rapid BK virus LAMP detection technology based on loop-mediated isothermal amplification (LAMP), which develops a colorimetric method completing testing within 20 minutes with a limit of detection of 10⁴ copies/μl—far faster than the 5 hours required by traditional methods—providing a rapid, sensitive tool for viral monitoring of post-transplant patients and supporting early intervention and protection of graft function.

Although the event has come to an end, innovation will never stop. AlloDx will continue to uphold the corporate philosophy of striving for innovation and continue to promote the development and advancement of diagnostic technology in the fields of kidney disease and transplantation.